FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385973399> ?p ?o ?g. }

• W4385973399 endingPage "100342" @default.
• W4385973399 startingPage "100342" @default.
• W4385973399 abstract "Understanding the clinical potency of latency-reversing agents (LRAs) on the HIV-1 reservoir is useful to deploy future strategies. This systematic review evaluated the effects of LRAs in human intervention studies.A literature search was performed using medical databases focusing on studies with adults living with HIV-1 receiving LRAs. Eligibility criteria required participants from prospective clinical studies, a studied compound hypothesised as LRA, and reactivation or tolerability assessments. Relevant demographical data, LRA reactivation capacity, reservoir size, and adverse events were extracted. A study quality assessment with analysis of bias was performed by RoB 2 and ROBINS-I tools. The primary endpoints were HIV-1 reservoir reactivation after LRA treatment quantified by cell-associated unspliced HIV-1 RNA, and LRA tolerability defined by adverse events. Secondary outcomes were reservoir size and the effect of LRAs on analytical treatment interruption (ATI) duration.After excluding duplicates, 5182 publications were screened. In total 45 publications fulfilled eligibility criteria including 26 intervention studies and 16 randomised trials. The risk of bias was evaluated as high. Chromatin modulators were the main investigated LRA class in 24 studies. Participants were mostly males (90.1%). Where reported, HIV-1 subtype B was most frequently observed. Reactivation after LRA treatment occurred in 78% of studies and was observed with nearly all chromatin modulators. When measured, reactivation mostly occurred within 24 h after treatment initiation. Combination LRA strategies have been infrequently studied and were without synergistic reactivation. Adverse events, where reported, were mostly low grade, yet occurred frequently. Seven studies had individuals who discontinued LRAs for related adverse events. The reservoir size was assessed by HIV-1 DNA in 80% of studies. A small decrease in reservoir was observed in three studies on immune checkpoint inhibitors and the histone deacetylase inhibitors romidepsin and chidamide. No clear effect of LRAs on ATI duration was observed.This systematic review provides a summary of the reactivation of LRAs used in current clinical trials whilst highlighting the importance of pharmacovigilance. Highly heterogeneous study designs and underrepresentation of relevant patient groups are to be considered when interpreting these results. The observed reactivation did not lead to cure or a significant reduction in the size of the reservoir. Finding more effective LRAs by including well-designed studies are needed to define the required reactivation level to reduce the HIV-1 reservoir." @default.
• W4385973399 created "2023-08-19" @default.
• W4385973399 creator A5015714125 @default.
• W4385973399 creator A5027158786 @default.
• W4385973399 creator A5055854863 @default.
• W4385973399 creator A5056575262 @default.
• W4385973399 creator A5059563743 @default.
• W4385973399 creator A5060824953 @default.
• W4385973399 creator A5077282469 @default.
• W4385973399 creator A5092660224 @default.
• W4385973399 date "2023-09-01" @default.
• W4385973399 modified "2023-10-14" @default.
• W4385973399 title "The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review" @default.
• W4385973399 cites W1497870368 @default.
• W4385973399 cites W1936344549 @default.
• W4385973399 cites W1963802821 @default.
• W4385973399 cites W1965266980 @default.
• W4385973399 cites W1971112771 @default.
• W4385973399 cites W2037524921 @default.
• W4385973399 cites W2055796578 @default.
• W4385973399 cites W2071960376 @default.
• W4385973399 cites W2074061250 @default.
• W4385973399 cites W2098194107 @default.
• W4385973399 cites W2102226008 @default.
• W4385973399 cites W2108696783 @default.
• W4385973399 cites W2109010689 @default.
• W4385973399 cites W2120014878 @default.
• W4385973399 cites W2124058652 @default.
• W4385973399 cites W2151980311 @default.
• W4385973399 cites W2158867438 @default.
• W4385973399 cites W2177904182 @default.
• W4385973399 cites W2331886819 @default.
• W4385973399 cites W2410813747 @default.
• W4385973399 cites W2417209002 @default.
• W4385973399 cites W2418641901 @default.
• W4385973399 cites W2470126287 @default.
• W4385973399 cites W2471940872 @default.
• W4385973399 cites W2494142260 @default.
• W4385973399 cites W2531269403 @default.
• W4385973399 cites W2560438049 @default.
• W4385973399 cites W2593700719 @default.
• W4385973399 cites W2735653597 @default.
• W4385973399 cites W2752078504 @default.
• W4385973399 cites W2785480387 @default.
• W4385973399 cites W2887660850 @default.
• W4385973399 cites W2920596526 @default.
• W4385973399 cites W2923403959 @default.
• W4385973399 cites W2925601131 @default.
• W4385973399 cites W2936167073 @default.
• W4385973399 cites W2961032267 @default.
• W4385973399 cites W2970684805 @default.
• W4385973399 cites W2990648940 @default.
• W4385973399 cites W3006940104 @default.
• W4385973399 cites W3011821849 @default.
• W4385973399 cites W3019350884 @default.
• W4385973399 cites W3022680181 @default.
• W4385973399 cites W3043410578 @default.
• W4385973399 cites W3083249584 @default.
• W4385973399 cites W3091821209 @default.
• W4385973399 cites W3116113145 @default.
• W4385973399 cites W3116979177 @default.
• W4385973399 cites W3117720485 @default.
• W4385973399 cites W3123893780 @default.
• W4385973399 cites W3135286008 @default.
• W4385973399 cites W3155149291 @default.
• W4385973399 cites W3162836223 @default.
• W4385973399 cites W3199051319 @default.
• W4385973399 cites W3203007817 @default.
• W4385973399 cites W3215829698 @default.
• W4385973399 cites W4207008834 @default.
• W4385973399 cites W4210518019 @default.
• W4385973399 cites W4210750489 @default.
• W4385973399 cites W4213206827 @default.
• W4385973399 cites W4226353892 @default.
• W4385973399 cites W4236805817 @default.
• W4385973399 cites W4288904229 @default.
• W4385973399 cites W4292371797 @default.
• W4385973399 cites W4306411715 @default.
• W4385973399 cites W4321369629 @default.
• W4385973399 cites W4324324998 @default.
• W4385973399 doi "https://doi.org/10.1016/j.jve.2023.100342" @default.
• W4385973399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37663575" @default.
• W4385973399 hasPublicationYear "2023" @default.
• W4385973399 type Work @default.
• W4385973399 citedByCount "0" @default.
• W4385973399 crossrefType "journal-article" @default.
• W4385973399 hasAuthorship W4385973399A5015714125 @default.
• W4385973399 hasAuthorship W4385973399A5027158786 @default.
• W4385973399 hasAuthorship W4385973399A5055854863 @default.
• W4385973399 hasAuthorship W4385973399A5056575262 @default.
• W4385973399 hasAuthorship W4385973399A5059563743 @default.
• W4385973399 hasAuthorship W4385973399A5060824953 @default.
• W4385973399 hasAuthorship W4385973399A5077282469 @default.
• W4385973399 hasAuthorship W4385973399A5092660224 @default.
• W4385973399 hasBestOaLocation W43859733991 @default.
• W4385973399 hasConcept C126322002 @default.
• W4385973399 hasConcept C197934379 @default.
• W4385973399 hasConcept C203014093 @default.

• next